Denali Therapeutics Inc. (DNLI) Q3 2025 10-Q Quarterly Report
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Denali Therapeutics Inc. (DNLI) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Denali Therapeutics Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New clinical trial failure risk: Phase 2/3 HEALEY ALS Platform Trial of DNL343 missed primary/secondary endpoints in Jan 2025, raising pipeline uncertainty
- • Updated financial risk: Net loss increased to $126.9M Q3 2025 vs $107.2M Q3 2024, accumulated deficit $1.92B as of Sept 30, 2025
Denali Therapeutics Inc. Q3 2025 Quarterly FinancialsXBRL
Net Income
-$127M
▼ -18.4% YoY▼ -2.2% QoQ
ROE
-13.7%
Total Assets
$1.1B
EPS (Diluted)
$-0.74
▼ -17.5% YoY▼ -2.8% QoQ
Operating Cash Flow
-$107M
▼ -81.4% YoY▼ -42.5% QoQ
Source: XBRL data from Denali Therapeutics Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Denali Therapeutics Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.